ID   CDO1_HUMAN              Reviewed;         200 AA.
AC   Q16878; B2RAK4; P78513; Q6FHZ8; Q8TB64;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   15-MAR-2017, entry version 145.
DE   RecName: Full=Cysteine dioxygenase type 1;
DE            EC=1.13.11.20;
DE   AltName: Full=Cysteine dioxygenase type I;
DE            Short=CDO;
DE            Short=CDO-I;
GN   Name=CDO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-45.
RC   TISSUE=Liver;
RX   PubMed=7524679; DOI=10.1016/0167-4838(94)90144-9;
RA   McCann K.P., Akbari M.T., Williams A.C., Ramsden D.B.;
RT   "Human cysteine dioxygenase type I: primary structure derived from
RT   base sequencing of cDNA.";
RL   Biochim. Biophys. Acta 1209:107-110(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], INDUCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=10427686; DOI=10.1271/bbb.63.1017;
RA   Tsuboyama-Kasaoka N., Hosokawa Y., Kodama H., Matsumoto A., Oka J.,
RA   Totani M.;
RT   "Human cysteine dioxygenase gene: structural organization, tissue-
RT   specific expression and downregulation by phorbol 12-myristate 13-
RT   acetate.";
RL   Biosci. Biotechnol. Biochem. 63:1017-1024(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-45.
RX   PubMed=9497919; DOI=10.1136/mp.50.5.269;
RA   Ramsden D.B., Kapadi A.L., Fitch N.J., Farmer M.J., Bennett P.,
RA   Williams A.C.;
RT   "Human cysteine dioxygenase type I (CDO-I; EC 1.13.11.20): 5' flanking
RT   region and intron-exon structure of the gene.";
RL   Mol. Pathol. 50:269-271(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S.,
RA   Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA   Korn B., Zuo D., Hu Y., LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 2-200 OF WILD-TYPE AND
RP   MUTANTS ARG-60; CYS-93; TYR-157 AND CYS-164 IN COMPLEX WITH L-CYSTEINE
RP   AND DIVALENT METAL IONS, CROSS-LINK, SUBUNIT, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=17135237; DOI=10.1074/jbc.M609337200;
RA   Ye S., Wu X., Wei L., Tang D., Sun P., Bartlam M., Rao Z.;
RT   "An insight into the mechanism of human cysteine dioxygenase. Key
RT   roles of the thioether-bonded tyrosine-cysteine cofactor.";
RL   J. Biol. Chem. 282:3391-3402(2007).
RN   [10]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-143.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Initiates several important metabolic pathways related
CC       to pyruvate and several sulfurate compounds including sulfate,
CC       hypotaurine and taurine. Critical regulator of cellular cysteine
CC       concentrations. Has an important role in maintaining the hepatic
CC       concentation of intracellular free cysteine within a proper narrow
CC       range.
CC   -!- CATALYTIC ACTIVITY: L-cysteine + O(2) = 3-sulfinoalanine.
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC       Note=Binds 1 Fe(2+) cation per subunit. Zn(2+) can be used to a
CC       much lesser extent.;
CC   -!- PATHWAY: Organosulfur biosynthesis; taurine biosynthesis;
CC       hypotaurine from L-cysteine: step 1/2.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:17135237}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver and placenta. Low
CC       expression in heart, brain and pancreas. Also detected in
CC       hepatoblastoma Hep-G2 cells. {ECO:0000269|PubMed:10427686}.
CC   -!- INDUCTION: In hepatoblastoma Hep-G2 cells, down-regulated by
CC       phorbol 12-myristate 13-acetate (PMA).
CC       {ECO:0000269|PubMed:10427686}.
CC   -!- PTM: The thioether cross-link between Cys-93 and Tyr-157 plays a
CC       structural role through stabilizing the Fe(2+) ion, and prevents
CC       the production of highly damaging free hydroxyl radicals by
CC       holding the oxygen radical via hydroxyl hydrogen.
CC       {ECO:0000269|PubMed:17135237}.
CC   -!- SIMILARITY: Belongs to the cysteine dioxygenase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z31357; CAA83234.1; -; mRNA.
DR   EMBL; Z23010; CAA80552.1; -; mRNA.
DR   EMBL; D85782; BAA12873.1; -; Genomic_DNA.
DR   EMBL; D85777; BAA12872.1; -; mRNA.
DR   EMBL; AK314231; BAG36901.1; -; mRNA.
DR   EMBL; U80055; AAB58352.1; -; Genomic_DNA.
DR   EMBL; U60232; AAB58352.1; JOINED; Genomic_DNA.
DR   EMBL; U78979; AAB58352.1; JOINED; Genomic_DNA.
DR   EMBL; CR536540; CAG38777.1; -; mRNA.
DR   EMBL; CH471086; EAW48957.1; -; Genomic_DNA.
DR   EMBL; BC024241; AAH24241.1; -; mRNA.
DR   CCDS; CCDS4121.1; -.
DR   PIR; S50192; S50192.
DR   RefSeq; NP_001310494.1; NM_001323565.1.
DR   RefSeq; NP_001310495.1; NM_001323566.1.
DR   RefSeq; NP_001310496.1; NM_001323567.1.
DR   RefSeq; NP_001792.2; NM_001801.2.
DR   UniGene; Hs.442378; -.
DR   PDB; 2IC1; X-ray; 2.70 A; A=1-200.
DR   PDBsum; 2IC1; -.
DR   ProteinModelPortal; Q16878; -.
DR   SMR; Q16878; -.
DR   BioGrid; 107468; 9.
DR   IntAct; Q16878; 2.
DR   STRING; 9606.ENSP00000250535; -.
DR   DrugBank; DB00151; L-Cysteine.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; Q16878; -.
DR   PhosphoSitePlus; Q16878; -.
DR   BioMuta; CDO1; -.
DR   DMDM; 76800649; -.
DR   EPD; Q16878; -.
DR   PaxDb; Q16878; -.
DR   PeptideAtlas; Q16878; -.
DR   PRIDE; Q16878; -.
DR   DNASU; 1036; -.
DR   Ensembl; ENST00000250535; ENSP00000250535; ENSG00000129596.
DR   GeneID; 1036; -.
DR   KEGG; hsa:1036; -.
DR   UCSC; uc003krg.4; human.
DR   CTD; 1036; -.
DR   DisGeNET; 1036; -.
DR   GeneCards; CDO1; -.
DR   HGNC; HGNC:1795; CDO1.
DR   HPA; HPA036573; -.
DR   HPA; HPA057503; -.
DR   MalaCards; CDO1; -.
DR   MIM; 603943; gene.
DR   neXtProt; NX_Q16878; -.
DR   OpenTargets; ENSG00000129596; -.
DR   PharmGKB; PA26327; -.
DR   eggNOG; KOG4064; Eukaryota.
DR   eggNOG; ENOG410XQM4; LUCA.
DR   GeneTree; ENSGT00390000018226; -.
DR   HOGENOM; HOG000177818; -.
DR   HOVERGEN; HBG004469; -.
DR   InParanoid; Q16878; -.
DR   KO; K00456; -.
DR   OMA; DASRGYT; -.
DR   OrthoDB; EOG091G0LAR; -.
DR   PhylomeDB; Q16878; -.
DR   TreeFam; TF105636; -.
DR   BioCyc; MetaCyc:HS05299-MONOMER; -.
DR   BRENDA; 1.13.11.20; 2681.
DR   Reactome; R-HSA-1614558; Degradation of cysteine and homocysteine.
DR   SignaLink; Q16878; -.
DR   SIGNOR; Q16878; -.
DR   UniPathway; UPA00012; UER00537.
DR   EvolutionaryTrace; Q16878; -.
DR   GenomeRNAi; 1036; -.
DR   PRO; PR:Q16878; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000129596; -.
DR   CleanEx; HS_CDO1; -.
DR   Genevisible; Q16878; HS.
DR   GO; GO:0005829; C:cytosol; TAS:UniProtKB.
DR   GO; GO:0017172; F:cysteine dioxygenase activity; ISS:UniProtKB.
DR   GO; GO:0008198; F:ferrous iron binding; IEA:Ensembl.
DR   GO; GO:0006534; P:cysteine metabolic process; TAS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; TAS:UniProtKB.
DR   GO; GO:0019448; P:L-cysteine catabolic process; TAS:Reactome.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0055114; P:oxidation-reduction process; TAS:UniProtKB.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0033762; P:response to glucagon; IEA:Ensembl.
DR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.
DR   GO; GO:0000097; P:sulfur amino acid biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0042412; P:taurine biosynthetic process; TAS:UniProtKB.
DR   Gene3D; 2.60.120.10; -; 1.
DR   InterPro; IPR010300; CDO_1.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR011051; RmlC_Cupin.
DR   PANTHER; PTHR12918; PTHR12918; 1.
DR   Pfam; PF05995; CDO_I; 1.
DR   SUPFAM; SSF51182; SSF51182; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Dioxygenase; Iron; Metal-binding;
KW   Oxidoreductase; Polymorphism; Reference proteome; Thioether bond.
FT   CHAIN         1    200       Cysteine dioxygenase type 1.
FT                                /FTId=PRO_0000206606.
FT   METAL        86     86       Iron; via tele nitrogen; catalytic.
FT                                {ECO:0000269|PubMed:17135237}.
FT   METAL        88     88       Iron; via tele nitrogen; catalytic.
FT                                {ECO:0000269|PubMed:17135237}.
FT   METAL       140    140       Iron; via tele nitrogen; catalytic.
FT                                {ECO:0000269|PubMed:17135237}.
FT   CROSSLNK     93    157       3'-(S-cysteinyl)-tyrosine (Cys-Tyr).
FT                                {ECO:0000269|PubMed:17135237}.
FT   VARIANT      45     45       T -> I (in dbSNP:rs1042867).
FT                                {ECO:0000269|PubMed:7524679,
FT                                ECO:0000269|PubMed:9497919}.
FT                                /FTId=VAR_023536.
FT   VARIANT     143    143       E -> Q (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036170.
FT   MUTAGEN      60     60       R->Q: Reduces enzyme activity by 70%.
FT                                Reduces iron and zinc incorporation by
FT                                50%.
FT   MUTAGEN      93     93       C->S: Reduces enzyme activity and iron
FT                                incorporation by 50%. Zinc incorporation
FT                                increased by 20%.
FT   MUTAGEN     157    157       Y->F: Almost total loss of enzyme
FT                                activity and iron incorporation. Reduces
FT                                zinc incorporation by 20%.
FT   MUTAGEN     164    164       C->S: Reduces enzyme activity by 20%.
FT                                Little effect on iron incorporation. No
FT                                effect on zinc incorporation.
FT   CONFLICT    137    137       I -> V (in Ref. 7; AAH24241).
FT                                {ECO:0000305}.
FT   HELIX        12     22       {ECO:0000244|PDB:2IC1}.
FT   HELIX        30     39       {ECO:0000244|PDB:2IC1}.
FT   HELIX        44     47       {ECO:0000244|PDB:2IC1}.
FT   HELIX        48     50       {ECO:0000244|PDB:2IC1}.
FT   STRAND       55     57       {ECO:0000244|PDB:2IC1}.
FT   STRAND       59     64       {ECO:0000244|PDB:2IC1}.
FT   HELIX        66     68       {ECO:0000244|PDB:2IC1}.
FT   STRAND       71     77       {ECO:0000244|PDB:2IC1}.
FT   STRAND       92    100       {ECO:0000244|PDB:2IC1}.
FT   STRAND      102    107       {ECO:0000244|PDB:2IC1}.
FT   STRAND      119    124       {ECO:0000244|PDB:2IC1}.
FT   STRAND      130    133       {ECO:0000244|PDB:2IC1}.
FT   TURN        135    137       {ECO:0000244|PDB:2IC1}.
FT   STRAND      139    144       {ECO:0000244|PDB:2IC1}.
FT   STRAND      147    149       {ECO:0000244|PDB:2IC1}.
FT   STRAND      151    159       {ECO:0000244|PDB:2IC1}.
FT   STRAND      162    167       {ECO:0000244|PDB:2IC1}.
FT   TURN        169    171       {ECO:0000244|PDB:2IC1}.
FT   STRAND      174    178       {ECO:0000244|PDB:2IC1}.
FT   STRAND      182    184       {ECO:0000244|PDB:2IC1}.
SQ   SEQUENCE   200 AA;  22972 MW;  E4EF87221D05C14D CRC64;
     MEQTEVLKPR TLADLIRILH QLFAGDEVNV EEVQAIMEAY ESDPTEWAMY AKFDQYRYTR
     NLVDQGNGKF NLMILCWGEG HGSSIHDHTN SHCFLKMLQG NLKETLFAWP DKKSNEMVKK
     SERVLRENQC AYINDSIGLH RVENISHTEP AVSLHLYSPP FDTCHAFDQR TGHKNKVTMT
     FHSKFGIRTP NATSGSLENN
//
